Omada Health, Inc. (NASDAQ: OMDA) Chief Accounting Officer Craig Gracey has executed a series of stock transactions totaling $85,423 in value. The divestment activity took place over a four-day window between June 26 and June 29, 2026, with share prices fluctuating between $20.00 and $21.00 per share during the execution period.
According to regulatory filings, Gracey disposed of 2,084 shares on June 26 at a price point of $20.00. He subsequently sold an additional 2,083 shares on June 29, closing out the series at $21.00 per share. These transactions were conducted pursuant to a 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged stock sales. The plan was originally adopted by Gracey on March 13, 2026, setting the framework for the recent activity.
The timing of these sales warrants attention given the stock's recent performance. Omada Health shares have appreciated by 20% over the past week, reaching a trading level of $21.95. Market analysis platforms, specifically InvestingPro, have flagged the current valuation as potentially overextended based on Fair Value assessments. Furthermore, technical indicators such as the Relative Strength Index (RSI) suggest the stock may be entering overbought territory, providing a technical context for the timing of the insider divestment.
Following the completion of these transactions, Craig Gracey's direct ownership stake in Omada Health has been reduced to 858 shares. The platform's analytical tools note that 12 additional ProTips and comprehensive Pro Research Reports are available for investors seeking deeper insights into Omada Health and over 1,400 other US equities.
In parallel with the insider activity, Omada Health reported its financial results for the first quarter of 2026, delivering a positive earnings surprise. The company posted an earnings per share (EPS) of -$0.05, outperforming the consensus estimate of -$0.08. Revenue for the quarter reached $78 million, marking a substantial 42% year-over-year increase.
Market sentiment towards the company also saw a recent adjustment. Citizens raised its price target for Omada Health to $21, up from $18, while maintaining a Market Outperform rating. Analyst Constantine Davides from Citizens noted that the stock was recently trading at 2.5 times the firm's 2026 revenue estimate, highlighting the valuation context within which these financial results were released.
On the corporate governance front, Omada Health conducted its 2026 Annual Meeting of Stockholders. During this meeting, Sean Duffy and Trevor Fetter were elected as Class I Directors. Both directors are appointed to serve until the annual meeting scheduled for 2029.
The stock's market data reflects ongoing trading activity, with the closing price recorded at $21.95, representing a gain of $0.28 or 1.29%. After-hours trading showed a slight pullback to $21.75, a decline of $0.20 or 0.91%. The company's valuation metrics and insider transactions remain key focal points for analysts monitoring the health tech sector.